08:47 AM EDT, 06/18/2025 (MT Newswires) -- Aptevo Therapeutics ( APVO ) said Wednesday that its mipletamig combination therapy achieved an 85% remission rate in frontline Acute myeloid leukemia patients.

The triplet therapy with venetoclax and azacitidine showed no dose-limiting toxicities or cytokine release syndrome, the company said.

Mipletamig's approach demonstrated strong efficacy and safety in patients unfit for chemotherapy, according to the phase 1b/2 Rainer trial results, Aptevo said.

The company also said three patients, including one previously ineligible for transplant, achieved complete remission, including MRD-negative status.

Group 3 of the trial is nearing full enrollment at the highest dose level tested, with the company optimistic about mipletamig's potential, it said.

Shares of the company were up over 141% in recent Wednesday premarket activity.

Price: 6.82, Change: +4.00, Percent Change: +141.84